Kurma Partners
Kurma Partners is a Paris-based venture capital firm established in 2009, focusing on early-stage investments in the healthcare and biotechnology sectors across Europe. The firm specializes in financing innovation from pre-creation to development capital, managing multiple funds, including the Kurma Biofund I, II, and the Kurma Diagnostics fund. Kurma Partners plays a significant role in supporting therapeutic and medical innovations, leveraging connections with leading research institutes and prestigious hospitals. The firm's investment interests encompass a wide range of areas, including oncology, life sciences, digital health, artificial intelligence, and big data, demonstrating a commitment to advancing healthcare technologies.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.
Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.